A citation-based method for searching scientific literature

Qiwu Zhao, Haoran Feng, Zheyu Yang, Juyong Liang, Zhijian Jin, Lingxie Chen, Ling Zhan, Ming Xuan, Jiqi Yan, Jie Kuang, Xi Cheng, Ren Zhao, Weihua Qiu. Clin Transl Med 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
D I Gabrilovich, H L Chen, K R Girgis, H T Cunningham, G M Meny, S Nadaf, D Kavanaugh, D P Carbone. Nat Med 1996
100

Colorectal cancer.
Evelien Dekker, Pieter J Tanis, Jasper L A Vleugels, Pashtoon M Kasi, Michael B Wallace. Lancet 2019
100

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Jeffrey J Wallin, Johanna C Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Suzanne Jones, Genevive Hernandez, James Mier, Xian He, F Stephen Hodi,[...]. Nat Commun 2016
388
100

The Intersection between Tumor Angiogenesis and Immune Suppression.
Osama E Rahma, F Stephen Hodi. Clin Cancer Res 2019
131
100

Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans.
Juefang Ding, Xiaoyan Chen, Zhiwei Gao, Xiaojian Dai, Liang Li, Cen Xie, Haoyuan Jiang, Lijia Zhang, Dafang Zhong. Drug Metab Dispos 2013
67
100

Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges.
John D Martin, Giorgio Seano, Rakesh K Jain. Annu Rev Physiol 2019
168
100

Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7.
Ling Ma, Zhangding Wang, Mengyan Xie, Yunlin Quan, Weiyou Zhu, Fengming Yang, Chenhui Zhao, Yu Fan, Na Fang, Huning Jiang,[...]. Cell Death Dis 2020
29
100


Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma.
Anna Maria Wirsing, Ida Korsnes Ervik, Marit Seppola, Lars Uhlin-Hansen, Sonja Eriksson Steigen, Elin Hadler-Olsen. Mod Pathol 2018
41
100


Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
Jianming Xu, Jie Shen, Shanzhi Gu, Yun Zhang, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin,[...]. Clin Cancer Res 2021
101
100

Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Dongmei Chi, Baoqing Chen, Suping Guo, Kunhao Bai, Huali Ma, Yonghong Hu, Qiaoqiao Li, Yujia Zhu. Aging (Albany NY) 2021
3
100

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Bo Zhang, Ling Qi, Xi Wang, Jianping Xu, Yun Liu, Lan Mu, Xingyuan Wang, Lidan Bai, Jing Huang. Cancer Commun (Lond) 2020
23
100

Apatinib as an optional treatment in metastatic colorectal cancer.
Aiyi Li, Kong Wang, Aiguo Xu, Gang Wang, Yongchang Miao, Zhichao Sun, Jingyu Zhang. Medicine (Baltimore) 2019
11
100

A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Lijun Liang, Lei Wang, Panrong Zhu, Youyou Xia, Yun Qiao, Jiang Wu, Wei Zhuang, Jiayan Fei, Yixuan Wen, Xiaodong Jiang. Clin Colorectal Cancer 2018
25
100

Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Yu Zhang, Fei Wang, Hao-Ran Sun, Ya-Kai Huang, Jian-Peng Gao, Hua Huang. J Cancer Res Clin Oncol 2021
6
100

Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery.
Binfan Chen, Ang Gao, Bin Tu, Yonghui Wang, Xiaolu Yu, Yingshu Wang, Yanfeng Xiu, Bing Wang, Yakun Wan, Yongzhuo Huang. Biomaterials 2020
34
100

Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Jin Li, Shukui Qin, Jianming Xu, Weijian Guo, Jianping Xiong, Yuxian Bai, Guoping Sun, Yan Yang, Liwei Wang, Nong Xu,[...]. J Clin Oncol 2013
368
100

Apatinib for molecular targeted therapy in tumor.
Haijun Zhang. Drug Des Devel Ther 2015
135
100

Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
S Chouaib, M Z Noman, K Kosmatopoulos, M A Curran. Oncogene 2017
183
100


Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
Mingming Yu, Zhiwei Gao, Xiaojian Dai, Hui Gong, Lianshan Zhang, Xiaoyan Chen, Da-Fang Zhong, Sherwin K B Sy. Clin Pharmacokinet 2017
17
100

Burden of Gastric Cancer.
Aaron P Thrift, Hashem B El-Serag. Clin Gastroenterol Hepatol 2020
285
100

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.
Shu Tian, Haitian Quan, Chengying Xie, Haiyi Guo, Fangfang Lü, Yongping Xu, Jin Li, Liguang Lou. Cancer Sci 2011
336
100

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.
Kabir A Khan, Robert S Kerbel. Nat Rev Clin Oncol 2018
243
100

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
100

Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
Minoru Fukuchi, Toru Ishiguro, Kyoichi Ogata, Okihide Suzuki, Youichi Kumagai, Keiichiro Ishibashi, Hideyuki Ishida, Hiroyuki Kuwano, Erito Mochiki. Ann Surg Oncol 2015
75
100

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, Mayer N Fishman, David F McDermott, Daniel C Cho, Ulka Vaishampayan, Saby George, Thomas E Olencki, Jamal C Tarazi,[...]. Lancet Oncol 2018
242
100

Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response.
Jingjing He, Xinxin Xiong, Han Yang, Dandan Li, Xuefei Liu, Shuo Li, Shuangye Liao, Siyu Chen, Xizhi Wen, Kuai Yu,[...]. Cell Res 2022
4
100

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
Xiaofeng Chen, Xiaofeng Wu, Hao Wu, Yanhong Gu, Yang Shao, Qianwen Shao, Feipeng Zhu, Xiao Li, Xiaofeng Qian, Jun Hu,[...]. J Immunother Cancer 2020
28
100

Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial.
Xinni Chen, Shukui Qin, Shanzhi Gu, Zhenggang Ren, Zhendong Chen, Jianping Xiong, Ying Liu, Zhiqiang Meng, Xiao Zhang, Linna Wang,[...]. Int J Cancer 2021
3
100

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Magali Terme, Simon Pernot, Elie Marcheteau, Federico Sandoval, Nadine Benhamouda, Orianne Colussi, Olivier Dubreuil, Antoine F Carpentier, Eric Tartour, Julien Taieb. Cancer Res 2013
394
100

Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Chao Jing, Junyun Wang, Mingyue Zhu, Zhigang Bai, Baoyi Zhao, Jun Zhang, Jie Yin, Xiaobao Yang, Zongzhi Liu, Zhongtao Zhang,[...]. Cancer Immunol Immunother 2022
3
100


Apatinib has anti-tumor effects and induces autophagy in colon cancer cells.
Wu Lu, He Ke, Ding Qianshan, Wang Zhen, Xiang Guoan, Yu Honggang. Iran J Basic Med Sci 2017
36
100

Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Nazila Fathi Maroufi, Mohammad Reza Rashidi, Vahid Vahedian, Maryam Akbarzadeh, Amir Fattahi, Mohammad Nouri. Life Sci 2020
32
100

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202).
Xiang Wang, Ruixing Zhang, Nan Du, Mudan Yang, Aimin Zang, Likun Liu, Junyan Yu, Jinghua Gao, Junping Zhang, Zhanzhao Fu,[...]. Ther Adv Med Oncol 2020
8
100


The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
Dongxu Wang, Xu Yang, Junyu Long, Jianzhen Lin, Jinzhu Mao, Fucun Xie, Yunchao Wang, Yanyu Wang, Ziyu Xun, Yi Bai,[...]. Front Oncol 2021
9
100

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Elizabeth Allen, Arnaud Jabouille, Lee B Rivera, Inge Lodewijckx, Rindert Missiaen, Veronica Steri, Kevin Feyen, Jaime Tawney, Douglas Hanahan, Iacovos P Michael,[...]. Sci Transl Med 2017
354
100

Second-line therapies in advanced biliary tract cancers.
Sri Harsha Tella, Anuhya Kommalapati, Mitesh J Borad, Amit Mahipal. Lancet Oncol 2020
41
100


VEGF in Signaling and Disease: Beyond Discovery and Development.
Rajendra S Apte, Daniel S Chen, Napoleone Ferrara. Cell 2019
608
100

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Xuefeng Kan, Bin Liang, Guofeng Zhou, Bin Xiong, Feng Pan, Yanqiao Ren, Yanyan Cao, Jihua Wang, Fan Yang, Chuansheng Zheng. Front Oncol 2020
22
100

Colorectal cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ann Goding Sauer, Stacey A Fedewa, Lynn F Butterly, Joseph C Anderson, Andrea Cercek, Robert A Smith, Ahmedin Jemal. CA Cancer J Clin 2020
100

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
100

Apatinib Promotes Apoptosis of Pancreatic Cancer Cells through Downregulation of Hypoxia-Inducible Factor-1α and Increased Levels of Reactive Oxygen Species.
Ke He, Lu Wu, Qianshan Ding, Farhan Haider, Honggang Yu, Haihe Wang, Guoan Xiang. Oxid Med Cell Longev 2019
12
100

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Xichun Hu, Jian Zhang, Binghe Xu, Zefei Jiang, Joseph Ragaz, Zhongsheng Tong, Qingyuan Zhang, Xiaojia Wang, Jifeng Feng, Danmei Pang,[...]. Int J Cancer 2014
182
100

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
100

The biology of VEGF and its receptors.
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter. Nat Med 2003
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.